Adriamycin (doxorubicin) cardiotoxicity: a review

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Adriamycin (doxorubicin hydrochloride) is a vital antineoplastic agent for various cancers.
• Cardiac toxicity, specifically dose-dependent cardiomyopathy, is a significant limitation to its long-term administration.
• Factors like prior mediastinal radiation, left ventricular dysfunction, and advanced age exacerbate the risk of Adriamycin-induced cardiotoxicity.

Purpose of the Study:

• To review the risks and current management strategies for Adriamycin-induced cardiotoxicity.
• To highlight the need for predictive methods for Adriamycin-induced congestive heart failure (CHF).
• To provide guidelines for safe Adriamycin dosing to minimize cardiac complications.

Main Methods:

• Review of existing literature on Adriamycin (doxorubicin hydrochloride) cardiotoxicity.
• Discussion of diagnostic techniques such as endomyocardial biopsy and radionuclide ejection-fraction measurement.
• Analysis of dose-response data and patient risk factors.

Main Results:

• No noninvasive method currently predicts Adriamycin-induced CHF.
• Endomyocardial biopsy and radionuclide ejection-fraction measurement show promise for patient selection.
• Recommended cumulative doses to prevent CHF are 400-450 mg/m² after mediastinal radiation and 500-550 mg/m² for patients without other risk factors.

Conclusions:

• Preventing Adriamycin-induced CHF primarily relies on strict adherence to dose limitations.
• Further research into predictive diagnostics is needed for safer, long-term Adriamycin therapy.
• Optimizing dosing schedules, like weekly administration, may enhance therapeutic efficacy while managing cardiac risks.